X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
X4 Pharmaceuticals (NASDAQ: XFOR) said management will join a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami. A live and archived webcast will be available on the company’s Investors site under Events and Presentations.
Details
News Market Reaction – XFOR
On Mar 4, the day this news came out, XFOR closed 5.11% above the previous close.
Data tracked by StockTitan Argus for the Mar 4 session.
Key Figures
- Conference date
- March 11, 2026
- Leerink Global Healthcare Conference fireside chat
- Chat time
- 10:00 a.m. ET
- Scheduled start time of X4 fireside chat
Historical Context
-
CHMP positive opinion recommending EU approval of mavorixafor for WHIM.
-
Announcement of fireside chat and meetings at Guggenheim biotech summit.
-
Inducement stock options to new employees under equity incentive plan.
-
Participation in Guggenheim healthcare innovation conference with fireside chat.
-
Q3 2025 loss, large financings, workforce reduction, and strategy refocus.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL.
A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com
Source: X4 Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.